Background
Tinea nigra is an uncommon superficial dermatomycosis usually caused by Hortaea werneckii, formerly known as Phaeoannellomyces werneckii, (formerly classified as Exophiala werneckii and Cladosporium werneckii).[1] Tinea nigra may also be due to Stenella araguata, first described and named Cladosporium castellanii in 1973.[2] Tinea nigra appears as a hyperpigmented macule, which usually occurs on the palms. The soles and, more rarely, other areas of the body, can also be affected.
Cequeira first described tinea nigra in 1891, calling the infection keratomycosis nigricans palmaris. In 1921, Horta isolated the pathogen and gave it its original name, C werneckii.
Although P werneckii has been established as the causative fungus in most cases of tinea nigra, other species of dematiaceous fungi, such as S araguata, may produce a similar clinical picture.
A Cladophialophora strain, allegedly a new species, Cladophialophora saturnica, has been described that caused an interdigital tinea nigra – like lesion in a HIV-positive Brazilian child, successfully treated with oxiconazole.[3]
Pathophysiology
Tinea nigra is a superficial mycosis of the stratum corneum. Infection is believed to occur as a result of inoculation from a contamination source such as soil, sewage, wood, or compost subsequent to trauma in the affected area.
Typically, the incubation period for tinea nigra is 2-7 weeks, although in experimental inoculation, the incubation period was 20 years.[4] The fungus exhibits lipophilic adhesion to human skin; it is exclusively found in the stratum corneum and does not extend into the stratum lucidum.
P werneckii receives nourishment from its use of decomposed lipids. Its tolerance to an environment with a high salt concentration and a low pH allows the fungus to thrive in human skin. It has been isolated from the hypersaline waters of salterns as one of the predominant species of a group of halophilic and halotolerant melanized yeastlike fungi.[5] P werneckii has distinct mechanisms of adaptation to high-salinity environments that are not seen in salt-sensitive and only moderately salt–tolerant fungi.
A pigmentary change in the skin results in a dark-colored macule due to the accumulation of a melaninlike substance in the fungus.
Epidemiology
Frequency
United States
Tinea nigra is relatively uncommon in the United States. However, numerous cases are reported in the dermatologic literature. Tinea nigra typically affects people who reside in the coastal states such as Florida, Texas, Alabama, Louisiana, Virginia, and North Carolina. Although cases of tinea nigra are also reported in patients from northern and inland regions of the United States, including New York City, Chicago, and Boston, patients often report a history of foreign travel, frequently to the Caribbean Islands.[6]
International
Tinea nigra is not uncommon in tropical regions of Central America, South America, Africa, and Asia. Epidemiologic studies of skin diseases in schoolchildren performed by direct inspection using dermatologists in Magong, Penghu, Republic of China on the island of Formosa found the prevalence of fungal infection, including tinea nigra, tinea versicolor, and tinea corporis, to be 0.24% (95% confidence interval, 0.07-0.41%).[7] Tinea nigra may present as an imported infection from endemic areas into temperate climate regions.[6]
Mortality/Morbidity
Although the appearance of tinea nigra may be alarming because of its uncommon occurrence and its potential confusion with a more serious medical disorder (eg, malignant melanoma[8, 9] ), tinea nigra is a benign disease that is easily curable.
Race
Tinea nigra appears to occur less often in the black population than in others, although this observation may reflect impaired recognition of the disease.
Sex
The female-to-male predilection for tinea nigra is 3:1.
Age
Tinea nigra most often occurs in pediatric and adolescent populations; however, individuals of any age may be affected. In a study of 12 patients in Venezuela, it was found to be more prevalent among young people with fair skin aged 3-28 years who visited beaches.[2]
Schwartz RA. Superficial fungal infections. Lancet. Sep 25-Oct 1 2004;364(9440):1173-82. [Medline].
Perez C, Colella MT, Olaizola C, Hartung de Capriles C, Magaldi S, Mata-Essayag S. Tinea nigra: report of twelve cases in Venezuela. Mycopathologia. Oct 2005;160(3):235-8. [Medline].
Badali H, Carvalho VO, Vicente V, et al. Cladophialophora saturnica sp. nov., a new opportunistic species of Chaetothyriales revealed using molecular data. Med Mycol. Feb 2009;47(1):51-62. [Medline].
Blank H. Tinea nigra: a twenty-year incubation period?. J Am Acad Dermatol. Jul 1979;1(1):49-51. [Medline].
Lenassi M, Vaupotic T, Gunde-Cimerman N, Plemenitas A. The MAP kinase HwHog1 from the halophilic black yeast Hortaea werneckii: coping with stresses in solar salterns. Saline Systems. 2007;3:3. [Medline].
Rezusta A, Gilaberte Y, Betran A, Gene J, Querol I, Arias M, et al. Tinea nigra: a rare imported infection. J Eur Acad Dermatol Venereol. Jan 2010;24(1):89-91. [Medline].
Chen GY, Cheng YW, Wang CY, Hsu TJ, Hsu MM, Yang PT, et al. Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. J Formos Med Assoc. Jan 2008;107(1):21-9. [Medline].
Hall J, Perry VE. Tinea nigra palmaris: differentiation from malignant melanoma or junctional nevi. Cutis. Jul 1998;62(1):45-6. [Medline].
Tseng SS, Whittier S, Miller SR, Zalar GL. Bilateral tinea nigra plantaris and tinea nigra plantaris mimicking melanoma. Cutis. Oct 1999;64(4):265-8. [Medline].
Uezato H, Gushi M, Hagiwara K, Kayo S, Hosokawa A, Nonaka S. A case of tinea nigra palmaris in Okinawa, Japan. J Dermatol. Jan 2006;33(1):23-9. [Medline].
Zalaudek I, Giacomel J, Cabo H, Di Stefani A, Ferrara G, Hofmann-Wellenhof R, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. Dermatology. 2008;216(1):14-23. [Medline].
Paschoal FM, de Barros JA, de Barros DP, de Barros JC, Filho CD. Study of the dermatoscopic pattern of tinea nigra: report of 6 cases. Skinmed. Nov-Dec 2010;8(6):319-21. [Medline].
Tilak R, Singh S, Prakash P, Singh DP, Gulati AK. A case report of tinea nigra from North India. Indian J Dermatol Venereol Leprol. Sep-Oct 2009;75(5):538-9. [Medline].
Burke WA. Tinea nigra: treatment with topical ketoconazole. Cutis. Oct 1993;52(4):209-11. [Medline].
Marks JG Jr, King RD, Davis BM. Treatment of tinea nigra palmaris with miconazole. Arch Dermatol. Mar 1980;116(3):321-2. [Medline].
Shannon PL, Ramos-Caro FA, Cosgrove BF, Flowers FP. Treatment of tinea nigra with terbinafine. Cutis. Sep 1999;64(3):199-201. [Medline].
Babel DE, Pelachyk JM, Hurley JP. Tinea nigra masquerading as acral lentiginous melanoma. J Dermatol Surg Oncol. May 1986;12(5):502-4. [Medline].

